MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11255-026-05329-4

Медицинская библиотека · International urology and nephrology · 2026

Efficacy, safety, and quality of life outcomes of [177Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a GRADE-assessed systematic review, meta-analysis and trial sequential analysis.

Mubarika Moosa, Maaz Muhammad, Muhammad Awon, Emmama Syeda, Mazhar Zaroon, Khalid Muddassir, Kumari Jiya, Alamin Mohamed Hisham, Ayalew Biruk Demisse, Noor Huzaifa, Hassan Muhammad, Khawar Muneeb, Sadiq Muhammad Hussnain, Syed Ghulam M S, Evangelista Laura, Bomanji Jamshed

СтатьяОбзорПеревод в очереди

Аннотация

BACKGROUND AND

OBJECTIVE

Lutetium-177-PSMA radioligand therapy ([177Lu] Lu-PSMA) is an emerging targeted treatment for metastatic castration-resistant prostate cancer (mCRPC). We evaluated the comparative efficacy, safety, and quality-of-life (QoL) impact of [177Lu] Lu-PSMA versus contemporary standard-of-care (SOC) regimens in mCRPC.

METHODS

We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). Adult participants with PSMA-positive mCRPC (n = 2113) randomized to [177Lu] Lu-PSMA or SOC were included. Primary outcomes were overall survival (OS) and radiographic progression-free survival (rPFS). Secondary outcomes included PSA response, QoL (FACT-P), and adverse events. Treatment effects were pooled using random-effects models.

KEY FINDINGS AND LIMITATIONS: Six RCTs were analyzed. Primary intention-to-treat analysis did not demonstrate a statistically significant overall survival improvement (HR 0.81; 95% CI 0.62-1.06); however, sensitivity analysis adjusting for control-arm crossover suggested a survival benefit (HR 0.76; 95% CI 0.59-0.96). [1⁷⁷Lu] Lu-PSMA significantly improved rPFS (HR 0.55; 95% CI 0.43-0.71), PSA response (RR 2.33; 95% CI 1.38-3.93), and delayed QoL deterioration (HR 0.58; 95% CI 0.51-0.66). The intervention increased low-grade xerostomia and grade ≥ 3 thrombocytopenia, though overall severe adverse events were comparable to SOC. Limitations include inter-trial heterogeneity, control-arm crossover diluting ITT estimates, and imaging-based selection bias.

CONCLUSIONS AND CLINICAL IMPLICATIONS: [177Lu] Lu-PSMA improves rPFS, biochemical response, and QoL in mCRPC, with an OS benefit apparent after accounting for crossover. These findings support integrating [177Lu] Lu-PSMA into clinical practice. Additional trials are required to determine optimal treatment sequencing and efficacy in taxane-naïve populations.

PROSPERO REGISTRATION: The protocol of this systematic review and meta-analysis is registered under PROSPERO, having ID CRD420251151366.

Для цитирования: Mubarika Moosa, Maaz Muhammad, Muhammad Awon, Emmama Syeda, Mazhar Zaroon, Khalid Muddassir, Kumari Jiya, Alamin Mohamed Hisham, Ayalew Biruk Demisse, Noor Huzaifa, Hassan Muhammad, Khawar Muneeb, Sadiq Muhammad Hussnain, Syed Ghulam M S, Evangelista Laura, Bomanji Jamshed. Efficacy, safety, and quality of life outcomes of [177Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a GRADE-assessed systematic review, meta-analysis and trial sequential analysis.. International urology and nephrology. 2026. DOI: 10.1007/s11255-026-05329-4.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.